🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older Adults

RecruitingPhase 4Ages 19 Years - anyAllKorea University Guro Hospital
NCT07838298 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to compare immune responses to different influenza vaccine formulations in older adults and to understand how immune aging and repeated annual influenza vaccination affect these responses. The main questions it aims to answer are: * Do standard dose, MF59 adjuvanted, and high dose influenza vaccines produce different immune responses in adults aged 65 years or older? * How does immune aging affect responses to different influenza vaccine formulations? * How do immune responses change with repeated annual influenza vaccination, and do these changes differ among vaccine formulations? Researchers will compare older adults who receive a standard dose, MF59 adjuvanted, or high dose influenza vaccine. Younger adults aged 19-49 years who receive a standard dose influenza vaccine will also be included as a reference group to help evaluate age related differe

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Older adult group: aged 65 years or older * Younger reference group: aged 19 to 49 years * Able to receive influenza vaccination and complete the scheduled follow up Exclusion Criteria: * Receipt of an influenza vaccine or any other vaccine within 4 weeks prior to enrollment * Immunocompromised status, including ongoing chemotherapy or immunosuppressive therapy, high dose corticosteroid therapy, history of solid organ or hematopoietic stem cell transplantation, active malignancy, HIV infection, or other clinically significant immunocompromising conditions * Moderate or severe acute infection * History of allergic reaction to an influenza vaccine or any of its components, or any other condition that precludes influenza vaccination * Inability, as determined by the investigator, to understand the purpose and procedures of the study and provide voluntary informed consent
💊

What it tests

  • Standard dose influenza vaccine
  • MF59 adjuvanted influenza vaccine
  • High dose influenza vaccine
📍

Where

1 site
Korea University Guro Hospital
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy